Erin Huebschman
Family Medicine · Lancaster, WINPI 1790740223
Payments from drug & device makers
Across 147 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$288
- Astellas Pharma US Inc$280
- Lilly USA, LLC$243
- AbbVie$242
- Johnson & Johnson$238
- Amgen$178
- plus $881 from 16 others
What the payments were for
- Food & beverage$2,20294%
- Education$1476%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 18 | $288 |
| Astellas Pharma US Inc | 10 | $280 |
| Lilly USA, LLC | 22 | $243 |
| AbbVie | 16 | $242 |
| Johnson & Johnson | 15 | $238 |
| Amgen | 11 | $178 |
| Novo Nordisk | 7 | $124 |
| Pfizer | 9 | $122 |
| AstraZeneca | 7 | $107 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $96 |
| Lundbeck LLC | 3 | $58 |
| Merck | 4 | $58 |
| GSK | 4 | $54 |
| Dexcom, Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $49 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Bioventus LLC | 1 | $17 |
| Bayer | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,349 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 13 | $92,836 |
| LinzessLinaclotide | 21 | $12,152 |
| Potassium Chloride | 55 | $7,856 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 36 | $7,516 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $6,489 |
| MyrbetriqMirabegron | 37 | $6,068 |
| TegretolCarbamazepine | 13 | $5,381 |
| Dexlansoprazole DrDexlansoprazole | 18 | $3,764 |
| Aripiprazole | 13 | $2,716 |
| Darifenacin ErDarifenacin Hydrobromide | 13 | $2,303 |
| Unifine Safecontrol Pen NeedlePen Needle,dual Safety,diabetc | 19 | $1,157 |
| Metoprolol Succinate | 46 | $1,115 |
| Valproic AcidValproic Acid (As Sodium Salt) | 28 | $997 |
| Rosuvastatin Calcium | 37 | $951 |
| Valsartan | 17 | $909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $242 | $12,15221 claims |
| MerckJanumet Xr | $58 | $7,51636 claims |
| Astellas Pharma US IncMyrbetriq | $280 | $6,06837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Lancaster
- Taha El-ShahatMadison$15.6M
- Jonathan MeimanMadison$4.3M
- John AgaibyKenosha$4M
- John LaabsShawano$3.6M
- Jennifer ParsleyElk Mound$1.4M
- William PalinMilwaukee$693K
- Jonathan TemteMadison$542K
- Ryan AndrewsStevens Point$429K
- Tara DallDelafield$230K
- Mark JensonGreen Bay$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.